Chronic coronary syndrome (CCS) has been considered another comorbidity in previous studies, and there has been no significant reduction in cardiovascular mortality or myocardial infarction (MI) rates with revascularization through percutaneous coronary intervention (PCI) or myocardial revascularization surgery (MRS) compared with optimal medical treatment (OMT). One possible reason for the lack of benefit has been<a href="https://solaci.org/en/2023/09/21/ischemia-trial-does-complete-anatomical-or-functional-revascularization-modify-anything-compared-with-medical-treatment/" title="Read more" >...</a>
Is Complete Revascularization Really Necessary after AMI in the Elderly?
The population over 75 is growing gradually, which entails an increase in acute myocardial infarction (AMI) in this group. As we all know, it is fairly common for AMI to present with multivessel disease. It has been shown that younger patients will benefit from complete revascularization vs. a simple resolution of the culprit vessel. However,<a href="https://solaci.org/en/2023/09/13/is-complete-revascularization-really-necessary-after-ami-in-the-elderly/" title="Read more" >...</a>
ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction
Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies. In this context, the FIRE study looked to determine whether physiology guided complete revascularization is superior to culprit-only revascularization in elderly patients with multivessel disease suffering acute MI. The study included SCA patients over 75, hospitalized for both STEMI<a href="https://solaci.org/en/2023/08/29/esc-2023-fire-trial-physiology-guided-complete-revascularization-benefits-elderly-patients-with-myocardial-infarction/" title="Read more" >...</a>
BASIL-2: Revascularization of Infra-Popliteal Territory in Patients with Critical Lower Limb Ischemia
Results of infrapopliteal territory revascularization in critical limb ischemia. Compared against the general population, patients suffering from critical lower limb ischemia (CLI) not only experience seriously limited quality of life, but also face a significant higher risk of death and amputation. Specifically, the optimal treatment for these patients remains uncertain. This uncertainty was sparked by<a href="https://solaci.org/en/2023/06/22/basil-2-revascularization-of-infra-popliteal-territory-in-patients-with-critical-lower-limb-ischemia/" title="Read more" >...</a>
EuroPCR 2023 | iFR vs FFR Guided Revascularization in Left Main De Novo Lesions
Acute coronary syndrome guidelines recommend the use of iFR and FFR guided invasive management for patients with high risk ischemia regardless medical treatment. However, iFR and FFR they are often considered exchangeable. Prior literature has shown there can be a discrepancy of around 20% between these techniques when it comes to revascularization outcomes. Choosing the<a href="https://solaci.org/en/2023/05/17/europcr-2023-ifr-vs-ffr-guided-revascularization-in-left-main-de-novo-lesions/" title="Read more" >...</a>
Left Main Coronary Artery Revascularization: Are Periprocedural Complications Significant?
In the field of percutaneous coronary intervention (PCI) and myocardial revascularization surgery (MRS), previous analyses have shown a link between in-hospital and 30-day complications, in terms of complicated progress and/or mortality. Most of this information comes from non-randomized or old studies, which translates into contradictory data. Researchers analyzed the EXCEL study, which included patients with<a href="https://solaci.org/en/2023/03/22/left-main-coronary-artery-revascularization-are-periprocedural-complications-significant/" title="Read more" >...</a>
ACC 2023 | Complete Revascularization Strategies in patients with ACS and Multivessel Disease
In patients with acute coronary syndrome (ACS) and multivessel disease, complete revascularization is associated with better clinical outcomes. However, for non-culprit vessel revascularization the strategy remains unclear. The aim of this multicenter, open label, randomized, non-inferiority study, was to determine whether complete revascularization during index procedure is non inferior vs. staged. Primary end point was<a href="https://solaci.org/en/2023/03/08/acc-2023-complete-revascularization-strategies-in-patients-with-acs-and-multivessel-disease/" title="Read more" >...</a>
Left Main Revascularization: 12 Year Registry in Canada
The current indication for severe left main lesion continues to be coronary artery bypass graft surgery (CABG) but percutaneous coronary intervention (PCI) has come far in this territory thanks to increasing operator experienced and the use of IVUS during procedures. At present, left main disease have a Class IIa indication in the American guidelines when<a href="https://solaci.org/en/2023/03/02/left-main-revascularization-12-year-registry-in-canada/" title="Read more" >...</a>
Stent Revascularization in Femoropopliteal Disease: An Analysis of Clustered Randomized Trials
A study compared pooled data of claudication and critical ischemia patients treated with stenting vs. by-pass surgery in femoropopliteal disease. The main objective of revascularization in femoropopliteal disease is to improve the quality of life and functional capacity of claudication patients who did not respond to medical treatment, and to save the affected limb in<a href="https://solaci.org/en/2023/02/07/stent-revascularization-in-femoropopliteal-disease-an-analysis-of-clustered-randomized-trials/" title="Read more" >...</a>
Long-Term Evolution of Hybrid Coronary Revascularization
Currently, myocardial revascularization surgery (MRS) and percutaneous coronary intervention (PCI) are the available strategies for multivessel coronary artery disease. However, an alternative strategy has long been developed, called hybrid coronary revascularization (HCR), where the anterior descending artery is bypassed with a graft from the mammary artery and the rest of the lesions are treated by<a href="https://solaci.org/en/2023/01/23/long-term-evolution-of-hybrid-coronary-revascularization/" title="Read more" >...</a>